Athenex Inc (NASDAQ:ATNX) Director Jinn Wu bought 10,000 shares of the stock in a transaction dated Friday, February 9th. The stock was purchased at an average cost of $13.64 per share, for a total transaction of $136,400.00. Following the acquisition, the director now owns 249,208 shares of the company’s stock, valued at $3,399,197.12. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Athenex Inc (NASDAQ:ATNX) traded down $0.09 during midday trading on Friday, hitting $14.12. 353,645 shares of the company traded hands, compared to its average volume of 372,366. Athenex Inc has a 12-month low of $11.21 and a 12-month high of $20.79. The firm has a market capitalization of $783.52 and a PE ratio of -5.12.
Athenex (NASDAQ:ATNX) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) EPS for the quarter. sell-side analysts predict that Athenex Inc will post -2.3 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in ATNX. Bank of New York Mellon Corp acquired a new stake in shares of Athenex in the second quarter valued at about $240,000. Vanguard Group Inc. acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. California Public Employees Retirement System acquired a new stake in shares of Athenex in the second quarter valued at about $800,000. OxFORD Asset Management LLP acquired a new stake in shares of Athenex in the second quarter valued at about $956,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Athenex in the second quarter valued at about $320,000. Hedge funds and other institutional investors own 2.69% of the company’s stock.
Athenex Company Profile
Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.